First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: A case report

Ioannis G. Baraboutis; Vassilios Papastamopoulos; Georgios Charitsis; Lazaros J. Lekakis; Michael M. Vaslamatzis; Athanasios T. Skoutelis

doi:10.1097/MEG.0b013e3282f16411

First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: A case report

Ioannis G. Baraboutis, Vassilios Papastamopoulos, Georgios Charitsis, Lazaros J. Lekakis, Michael M. Vaslamatzis, Athanasios T. Skoutelis

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.

Original language	English (US)
Pages (from-to)	472-473
Number of pages	2
Journal	European Journal of Gastroenterology and Hepatology
Volume	20
Issue number	5
DOIs	https://doi.org/10.1097/MEG.0b013e3282f16411
State	Published - May 1 2008
Externally published	Yes

Keywords

Anti-vascular endothelium growth factor
Bevacizumab
HIV/hepatitis B virus coinfection
Metastatic hepatocellular carcinoma

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1097/MEG.0b013e3282f16411

Fingerprint Dive into the research topics of 'First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: A case report'. Together they form a unique fingerprint.

Cite this

Baraboutis, I. G., Papastamopoulos, V., Charitsis, G., Lekakis, L. J., Vaslamatzis, M. M., & Skoutelis, A. T. (2008). First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: A case report. European Journal of Gastroenterology and Hepatology, 20(5), 472-473. https://doi.org/10.1097/MEG.0b013e3282f16411

First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient : A case report. / Baraboutis, Ioannis G.; Papastamopoulos, Vassilios; Charitsis, Georgios; Lekakis, Lazaros J.; Vaslamatzis, Michael M.; Skoutelis, Athanasios T.

In: European Journal of Gastroenterology and Hepatology, Vol. 20, No. 5, 01.05.2008, p. 472-473.

Research output: Contribution to journal › Article › peer-review

Baraboutis, IG, Papastamopoulos, V, Charitsis, G, Lekakis, LJ, Vaslamatzis, MM & Skoutelis, AT 2008, 'First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: A case report', European Journal of Gastroenterology and Hepatology, vol. 20, no. 5, pp. 472-473. https://doi.org/10.1097/MEG.0b013e3282f16411

Baraboutis, Ioannis G. ; Papastamopoulos, Vassilios ; Charitsis, Georgios ; Lekakis, Lazaros J. ; Vaslamatzis, Michael M. ; Skoutelis, Athanasios T. / First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient : A case report. In: European Journal of Gastroenterology and Hepatology. 2008 ; Vol. 20, No. 5. pp. 472-473.

@article{83eb8eb1a5ea4e708591d90ff2c8f17a,

title = "First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: A case report",

abstract = "We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.",

keywords = "Anti-vascular endothelium growth factor, Bevacizumab, HIV/hepatitis B virus coinfection, Metastatic hepatocellular carcinoma",

author = "Baraboutis, {Ioannis G.} and Vassilios Papastamopoulos and Georgios Charitsis and Lekakis, {Lazaros J.} and Vaslamatzis, {Michael M.} and Skoutelis, {Athanasios T.}",

year = "2008",

month = may,

day = "1",

doi = "10.1097/MEG.0b013e3282f16411",

language = "English (US)",

volume = "20",

pages = "472--473",

journal = "European Journal of Gastroenterology and Hepatology",

issn = "0954-691X",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient

T2 - A case report

AU - Baraboutis, Ioannis G.

AU - Papastamopoulos, Vassilios

AU - Charitsis, Georgios

AU - Lekakis, Lazaros J.

AU - Vaslamatzis, Michael M.

AU - Skoutelis, Athanasios T.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.

AB - We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.

KW - Anti-vascular endothelium growth factor

KW - Bevacizumab

KW - HIV/hepatitis B virus coinfection

KW - Metastatic hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=42149167957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149167957&partnerID=8YFLogxK

U2 - 10.1097/MEG.0b013e3282f16411

DO - 10.1097/MEG.0b013e3282f16411

M3 - Article

C2 - 18403951

AN - SCOPUS:42149167957

VL - 20

SP - 472

EP - 473

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 5

ER -

First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: A case report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this